ArticleBone & joint research2025
Xuetongsu attenuates bone destruction in rheumatoid arthritis by suppressing RANKL/RANK/NFATc1 pathway to inhibit osteoclastogenesis and bone resorption.
Article in Bone & joint research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunopharmacological effects of shikonin in experimental rheumatoid arthritis: a systematic review and meta-analysis of in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Global burden of pain in malignant bone tumors: a meta-analysis of severity and health outcomes.Frontiers in oncology · 2026Pooled it
- Bioinspired 0D mitochondrial bioenergetic actuators rewire cartilage progenitor cell metabolism for osteoarthritis remission.Bioactive materials · 2026Article
- Plant-Derived Heterocyclic Compounds: A Promising Review on Natural Remedies for Rheumatoid Arthritis Management and Their Mechanistic Insights in Inflammation and Joint Protection.Basic & clinical pharmacology & toxicology · 2026Review
- Integrated LC-Orbitrap-MS and network pharmacology decipher the pharmacological basis of Eucommiae folium in treating rheumatoid arthritis.Molecular diversity · 2026Article
- Rutin as a multi-target anti-inflammatory phytochemical in arthritic disorders: pharmacological mechanisms and therapeutic potential.Inflammopharmacology · 2026Review
- Etoricoxib-Betamethasone Combination Attenuates Inflammatory Nociception and Edema in Adjuvant-Induced Arthritis via Cytokine and Macrophage Axis Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Promoting Bone Health in Layer Chickens from the Perspective of Mitochondrial Energy Metabolism in Osteoclasts.Animals : an open access journal from MDPI · 2026Review
- Comparative Efficacy and Safety of Intra-Articular Adipose-Derived, Bone Marrow-Derived, and Peripheral Blood-Derived Stem Cell Injections for Knee Osteoarthritis: A Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Sepsis in Autoimmune Rheumatic Diseases: Risk Factors, Pathophysiology, and Outcomes.Risk management and healthcare policy · 2026Review
- Neuro-immune-bone axis in post-traumatic bone regeneration: temporal regulation, dysregulation mechanisms, and therapeutic implications.Frontiers in immunology · 2026Review
- Apigenin Upregulates Regulatory B Cells, Suppresses Class Switch Recombination, and Restores Immune Homeostasis to Treat Autoimmune Arthritis and Sepsis.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Bone destruction is a pivotal pathological factor in the development of joint disability in rheumatoid arthritis (RA) patients, and there is a paucity of safe and effective drugs targeting bone destruction. Xuetong ( Methods: RA bone destruction is closely related to the activation of the RANKL/RANK/NFATc1 pathway. In this study, databases such as TDD were used for KEGG and GO enrichment analyses to identify the potential targets of Xuetongsu in regulating the RANKL/RANK/NFATc1 pathway for anti-RA bone destruction. Molecular docking was employed to evaluate the binding affinity and interaction sites between Xuetongsu and RANKL. For in vitro experiments, a RANKL-induced osteoclastogenesis model using RAW264.7 cells was established to assess Xuetongsu's effects on osteoclastogenesis and bone resorption capacity. In vivo, a stable adjuvant-induced arthritis rat model was developed to investigate the anti-bone destruction effects of oral Xuetongsu and systematically explore its underlying mechanisms. Results: Based on the findings from both in vitro and in vivo experimental models, it was revealed that Xuetongsu can directly target RANKL and inhibit the activation of the RANKL/RANK/NFATc1 pathway, thereby suppressing osteoclast-mediated bone resorption and preventing osteoclastogenesis. Conclusion: These findings indicate that Xuetongsu has been demonstrated to inhibit bone destruction by targeting the RANKL/RANK/NFATc1 pathway and could serve as a potential therapeutic agent for RA-associated bone destruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.